Complement Inhibition Therapy and Dialytic Strategies in Paroxysmal Nocturnal Hemoglobinuria: The Nephrologist's Opinion

被引:8
作者
Gembillo, Guido [1 ]
Siligato, Rossella [1 ]
Cernaro, Valeria [1 ]
Santoro, Domenico [1 ]
机构
[1] Univ Messina, Dept Clin & Expt Med, Unit Nephrol, I-98125 Messina, Italy
关键词
paroxysmal nocturnal hemoglobinuria; complement inhibition; eculizumab; ravulizumab; hemodialysis; PLASMA FILTRATION-ADSORPTION; ACUTE-RENAL-FAILURE; TAMM-HORSFALL PROTEIN; ACUTE KIDNEY INJURY; SOLUTE TRANSPORT; NATURAL-HISTORY; HIGH-FLUX; IN-VITRO; ECULIZUMAB; HEMOLYSIS;
D O I
10.3390/jcm9051261
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare clonal disease that presents an estimated incidence of 1.3 cases per million per year, with a prevalence of 15.9 cases per million. It is characterized by hemolysis, bone marrow dysfunction with peripheral blood cytopenia, hypercoagulability, thrombosis, renal impairment and arterial and pulmonary hypertension. Hemolysis and subsequent hemosiderin accumulation in tubular epithelium cells induce tubular atrophy and interstitial fibrosis. The origin of PNH is the somatic mutation in the X-linked phosphatidylinositol glycan class A (PIG-A) gene located on Xp22: this condition leads to the production of clonal blood cells with a deficiency in those surface proteins that protect against the lytic action of the activated complement system. Despite the increased knowledge of this syndrome, therapies for PNH were still only experimental and symptomatic, until the introduction of the C5 complement blockade agent Eculizumab. A second generation of anti-complement agents is currently under investigation, representing future promising therapeutic strategies for patients affected by PNH. In the case of chronic hemolysis and renal iron deposition, a multidisciplinary approach should be considered to avoid or treat acute tubular injury or acute kidney injury (AKI). New promising perspectives derive from complement inhibitors and iron chelators, as well as more invasive treatments such as immunoadsorption or the use of dedicated hemodialysis filters in the presence of AKI.
引用
收藏
页数:26
相关论文
共 181 条
  • [21] Paroxysmal nocturnal hemoglobinuria
    Brodsky, Robert A.
    [J]. BLOOD, 2014, 124 (18) : 2804 - 2811
  • [22] CLARK DA, 1981, BLOOD, V57, P83
  • [23] Solute Transport in Hemodialysis: Advances and Limitations of Current Membrane Technology
    Clark, William R.
    Gao, Dayong
    Neri, Mauro
    Ronco, Claudio
    [J]. EXPANDED HEMODIALYSIS: INNOVATIVE CLINICAL APPROACH IN DIALYSIS, 2017, 191 : 84 - 99
  • [24] COUTURIER C, 1991, J IMMUNOL, V147, P1899
  • [25] Adult Henoch-Schonlein purpura with glomerulonephritis and paroxysmal nocturnal haemoglobinuria: An uncommon association
    Cozzi, F
    Botsios, C
    Ostuni, P
    Sfriso, P
    Piva, E
    Marson, P
    Punzi, L
    Todesco, S
    [J]. CLINICAL RHEUMATOLOGY, 2002, 21 (05) : 408 - 410
  • [26] PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: FROM PHYSIOPATHOLOGY TO TREATMENT
    de Almeida Santos Arruda, Martha Mariana
    Rodrigues, Celso Arrais
    Yamamoto, Mihoko
    Figueiredo, Maria Stella
    [J]. REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2010, 56 (02): : 214 - 221
  • [27] Ten Years of Clinical Experience With Eculizumab in Patients With Paroxysmal Nocturnal Hemoglobinuria
    de Fontbrune, Flore Sicre
    de latour, Regis Peffault
    [J]. SEMINARS IN HEMATOLOGY, 2018, 55 (03) : 124 - 129
  • [28] Paroxysmal nocturnal hemoglobinuria:: natural history of disease subcategories
    de Latour, Regis Peffault
    Mary, Jean Yves
    Salanoubat, Celia
    Terriou, Louis
    Etienne, Gabriel
    Mohty, Mohamad
    Roth, Sophie
    de Guibert, Sophie
    Maury, Sebastien
    Cahn, Jean Yves
    Socie, Gerard
    [J]. BLOOD, 2008, 112 (08) : 3099 - 3106
  • [29] Dvanajscak Z, 2019, KIDNEY INT, V96, P1400, DOI [10.1016/j.kint.1019.08.026, 10.1016/j.kint.2019.08.026]
  • [30] Foreword
    Eckardt, Kai-Uwe
    Kasiske, Bertram L.
    [J]. KIDNEY INTERNATIONAL SUPPLEMENTS, 2012, 2 (01) : 7 - 7